Nasdaq

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication

GeneDx Recognizes Cerebral Palsy Awareness Month with Commitment to Improve Access to Testing GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes ...
Nasdaq

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...
Business Wire

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the commercial expansion into Inborn Errors of ...

Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrating the potential for variant-specific ...
Bloomberg L.P.

GeneDx Looks to Ramp Exome Testing: Vanguards of Health Care

"We are driving the market to exome and genome testing with a goal of making multi-gene panels be a thing of the past" Katherine Stueland, CEO of GeneDx, explains to Bloomberg Intelligence. Stueland ...
WDAF-TV

Study of More Than 18,000 Patients Finds Exome Sequencing Delivers Higher Diagnostic Rates for Autism Spectrum Disorders

GAITHERSBURG, Md., April 26, 2022 /PRNewswire/ -- GeneDx, LLC, a leader in genomic analysis, today unveiled new data demonstrating positive outcomes of exome analysis for individuals with autism ...
Morningstar

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing New data shows up to 61% reduction in healthcare costs for ...
Business Wire

Ambry Genetics Reports Specific Results from Clinical Diagnostic Exome™ Testing of Patients at Kennedy Krieger Institute

ALISO VIEJO, Calif. & BALTIMORE--(BUSINESS WIRE)--Ambry Genetics, a global leader in genetic services with a focus on clinical diagnostics and genomics, announces specific results from one of three ...
Seeking Alpha

GeneDx Reports First Quarter 2023 Financial Results and Business Highlights

Generated $40.7 million in first quarter 2023 pro forma revenue from continuing operations, representing a 7% increase year over year Revenue included $22.4 million in whole exome testing, ...